Stakeholder Opinions: Traumatic Brain Injury Hormonal therapy generates optimism

There remains no approved pharmacological or cellular treatment to improve the outcome of survivors of traumatic brain injury (TBI). In the past two decades, understanding of the cellular and molecular mechanisms that occur after TBI has grown and a combination of novel therapeutic strategies and approved molecules are presently being examined in clinical trials.( http://www.bharatbook.com/detail.asp?id=135953&rt=Stakeholder-Opinions-Traumatic-Brain-Injury-Hormonal-therapy-generates-optimism.html )

Scope

*Analysis of the patient potential of traumatic brain injury across the seven major markets and several rest of world markets.
*Review of key unmet clinical needs in the treatment of traumatic brain injury and current pipeline treatments.
*Identification of key opportunities and threats facing developers of treatments for traumatic brain injury.
*Insight from six internationally recognized key opinion leaders in the field of spinal cord injuries.

Highlights

The incidence of hospitalized cases of TBI is estimated to be higher than the annual incidence of several medical conditions including some cancer types, epilepsy, HIV/AIDS, multiple sclerosis and spinal cord injury. Therefore, developers of efficacious treatments for TBI stand to benefit from a sizeable patient population.

Despite the high level of unmet need in the treatment of TBI, TBI research is under-funded. The current situation may stem from poor awareness of TBI, pessimism resulting from the relatively high attrition rate in the TBI pipeline and the perception that an efficacious pharmacological treatment for TBI is unattainable.

A sizeable proportion of the clinical candidates are under development as neuroprotective treatments for TBI. The inclusion of two progesterone receptor agonists in the current pipeline is indicative of the rising level of optimism regarding the neuroprotective potential of progesterone in TBI.

Reasons to Purchase

*Quantify the incidence of hospitalized cases of TBI across the seven major pharmaceutical markets and identify key clinical unmet needs.
*Assess the opportunities and threats facing developers in the traumatic brain injury market.
*Utilize pipeline product profiles to identify potential in-licensing opportunities.

To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/detail.asp?id=135953&rt=Stakeholder-Opinions-Traumatic-Brain-Injury-Hormonal-therapy-generates-optimism.html

Or

Contact us at :

Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook

Bharat Book Bureau, the leading market research information aggregator provides reports, company profiles, newsletters, country info. and online databases for the past twenty two years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our reports help global companies to know different market before starting up business / expanding in different countries across the world.